



ADULT Medication Monograph

LABETALOL INJECTION

This document should be read in conjunction with this [DISCLAIMER](#)




[Formulary: Restricted](#)

[SAS Category A](#) (100mg/20mL vial)

Class	Beta blocker
Presentation	Vial: 100mg/20mL (SAS Category A) Vial: 50mg/10mL
Storage	Store below 30°C Ampoules: Protect from light Infusion solution: Discard 24 hours after preparation
Dose	IV injection: 20mg labetalol (4mL) undiluted over 2 minutes. Dose can be repeated every 10 minutes (titrated to blood pressure) to a maximum of 4 doses (80mg = 16mL). If 2 bolus doses are insufficient to control blood pressure, consider IV therapy via infusion. The maximal effect usually occurs within 5 minutes of each dose. IV infusion: See below Maximum total 24 hours dose is 300mg (injection plus infusion)
Administration	<u>IV Injection:</u> Inject undiluted solution over 2 minutes. <u>IV infusion:</u> <i>Step 1 Dilution:</i> Withdraw 40mL sodium chloride 0.9% from a 100mL bag of sodium chloride 0.9%. Draw up 200mg labetalol (40 mL) and add to remaining 60 mL in the bag of sodium chloride 0.9%. Final concentration is 2 mg/mL. <i>Step 2 Administration:</i> Start infusion at 10 mL/hour (20 mg/hour). Titrate to stabilise blood pressure by adjusting (doubling, maintaining or halving) the infusion as required every 15 to 30 minutes to a maximum dose of 80 mL/hour (160 mg/hour). Discontinue by weaning over 1-2 hours when clinically appropriate.

Pregnancy	<p>1st Trimester: Considered safe to use</p> <p>2nd Trimester: Monitoring required</p> <p>3rd Trimester: Monitoring required</p>
Breastfeeding	Considered safe to use
Monitoring	<ul style="list-style-type: none"> ➤ Blood pressure and heart rate should be monitored during and after completion of the infusion or intravenous injections ➤ Patients should always be kept in a supine position during and for up to 3 hours post IV drug administration due to potential orthostatic hypotension
Clinical Guidelines and Policies	<p>KEMH Clinical Guidelines:</p> <p>Hypertension in Pregnancy - Medical Management</p> <p>Hypertension in Pregnancy – Midwifery Care</p> <p>KEMH Pharmaceutical & Medicines Management Guidelines:</p> <p>KEMH Pharmaceutical & Medicines Management Guideline: Medication Administration</p>
References	<p>Society of Hospital Pharmacists of Australia. Labetalol. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2020 [cited 2020 Jun 10]. Available from: http://aidh.hcn.com.au</p> <p>The Royal Women's Hospital. Labetalol. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2020 [cited 2020 Jun 10]. Available from: https://thewomenspbmg.org.au/</p> <p>Lowe SA, Bowyer L, Lust K, McMahon LP, Morton MR, North RA, et al. Guideline for the management of hypertensive disorders of pregnancy. Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) Endorsed Guidelines [Internet]. 2014 [cited 2020 Jun 10].</p> <p>South Australian Maternal & Neonatal Community of Practice. Labetalol infusion regimen. South Australian Perinatal Practice Guidelines [Internet]. 2016 [cited 2020 Jun 10].</p> <p>South Australian Maternal, Neonatal & Gynaecology Community of Practice. Hypertensive Disorders in Pregnancy. South Australian Perinatal Practice Guidelines. [Internet]. 2019 [cited 2020 Jun 10].</p> <p>Ballarat Health Services. Labetalol (Intravenous - severe hypertension in pregnancy). Ballarat Health Services Drug Guideline DRG0035 [Internet]. 2014 [cited 2017 Mar 29].</p> <p>3centres Collaboration Consensus Guideline – Hypertension in Pregnancy, Preeclampsia and Eclampsia. [Internet] 2012 [cited 2020 Jun 10]. Available from: www.pers.org.au/Assets/45/1/3CENTRESPREECLAMPSIA.pdf</p> <p>McEvoy GK et al. Handbook on Injectable Drugs (Trissel): Labetalol</p>

	<p>hydrochloride. American Society of Health System Pharmacists. [Internet]. 2018. [cited 2020 Jun 10].</p> <p>Trandate Product information. Labetalol Hydrochloride Injection. Internet] 2010 [cited 2020 Jun 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019425s021lbl.pdf</p>
--	--

Keywords:	Labetalol Injection, labetalol infusion, hypertension in pregnancy, blood pressure, pre-eclampsia		
Publishing:	<input checked="" type="checkbox"/> Intranet <input checked="" type="checkbox"/> Internet		
Document owner:	Chief Pharmacist		
Author / Reviewer:	KEMH Pharmacy Department		
Date first issued:	May 2015	Version:	4.0
Last reviewed:	June 2020	Next review date:	June 2023
Endorsed by:	Medicines and Therapeutics Committee	Date:	May 2015
Standards Applicable:	NSQHS Standards: 1  Governance, 4  Medication Safety, 8  Acute Deterioration		
<p>Printed or personally saved electronic copies of this document are considered uncontrolled.</p> <p>Access the current version from the WNHS website.</p> <p>For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au</p>			

© Department of Health Western Australia 2020